Your Partner for Growth, Hybridan

Hybridan

Your Partner for Growth

Our passion is raising growth capital for exciting, fast growth companies that want to take their business to the next level. We raise capital for companies both listed and unlisted in the most efficient manner possible and pride ourselves as being one of the few consistently profitable broking firms in the City. This has been achieved through a highly disciplined approach when seeking to create both corporate and institutional relationships.

Equity Bottom-Up

<ul>
<li>Aptamer Group 0.33p £6.57m (APTA.L) The developer of novel Optimer binders to enable innovation in the life sciences industry yesterday reported Interims to December 2024.</li>
<li>Its revenue improved to £0.7m from £0.3m with an EBITDA loss of £1.1m down from £1.8m, while net cash is £2m after raising funds last year at 0.2p.</li>
<li>The strategy is to create value through the development of high-value Optimer assets with licensing potential through commercial partners, while generating revenues from fee-for-service work, which has a 43% gross margin. </li>
</ul>


Aptamer Group 0.33p £6.57m (APTA.L) The developer of novel Optimer binders to enable innovation in the life sciences industry yesterday reported Interims to December 2024.
Its revenue improved to £0.7m from £0.3m with an EBITDA loss of £1.1m down from £1.8m, while net cash is £2m after raising funds last year at 0.2p.
The strategy is to create value through the development of high-value Optimer assets with licensing potential through commercial partners, while generating revenues from fee-for-service work, which has a 43% gross margin. 


10X Genomics Inc-Class A - Hybridan Small Cap Feast: 12/03/2025

<ul>
<li>The medical technology Company is focussed on the durable healing of wounds and the prevention of amputations through its unique intermittent Topical Wound Oxygen (TWO2) and Negative Pressure Wound (NEXA) therapies, and this morning updated on trading for Y/E December 2024.</li>
<li>Revenue is expected to be more than $58.1m,which is 32% increase on 2023. Growth outside the Veterans Affairs (VA) sector has helped to diversify the sales mix such that the VA sector, whilst continuing to grow, accounted for less than 60% (2023: 72%) of Group revenues.</li>
<li>Investment in new market channels has given earlier access than planned to large and higher margin sectors. </li>
</ul>


The medical technology Company is focussed on the durable healing of wounds and the prevention of amputations through its unique intermittent Topical Wound Oxygen (TWO2) and Negative Pressure Wound (NEXA) therapies, and this morning updated on trading for Y/E December 2024.
Revenue is expected to be more than $58.1m,which is 32% increase on 2023. Growth outside the Veterans Affairs (VA) sector has helped to diversify the sales mix such that the VA sector, whilst continuing to grow, accounted for less than 60% (2023: 72%) of Group revenues.
Investment in new market channels has given earlier access than planned to large and higher margin sectors. 


Independent Investment Research, The IDEA!

The IDEA!

Independent Investment Research

The Idea-Driven Equities Analyses company (the IDEA!) is an employee-owned boutique providing independent investment research and financial consultancy services with a clear focus on the Benelux countries. The company was founded in the summer of 2007 by Henk Slotboom and Maarten Verbeek, both with more than 35 years of professional experience in the financial sector. The IDEA! differentiates itself by focusing on adding value through self-initiated in-depth, idea-driven investment research, as well as by bespoke research assignments for institutional investors, hedge funds and private equity. In addition, we provide market intelligence, strategic research and – together with our business partners – consultancy services to businesses. In case you are interested in receiving more information, a sample of our products or an introductory meeting, please send a message to info@theidea.nl.

<ul>
<li>In today's edition: • dsm-firmenich | sold its remainder ~1% stake in Robertet</li>
<li>KPN | Delta announced tariff increases as per 1 January 2025</li>
<li>Unilever | puts its efforts to sell its ice cream business to private equity on ice </li>
</ul>


In today's edition: • dsm-firmenich | sold its remainder ~1% stake in Robertet
KPN | Delta announced tariff increases as per 1 January 2025
Unilever | puts its efforts to sell its ice cream business to private equity on ice 


What's News in Amsterdam - 21 November (Dsm-Firmenich | KPN | Unilever | ForFarmers | PostNL)

Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

<ul><li>10x Genomics, a leading biotechnology company, presented its financial results for the third quarter ended September 30, 2024, during which the company experienced a 1% year-over-year decline in revenue.</li><li>This outcome was primarily attributed to disruptions stemming from a sales restructuring initiative and cautious customer spending amid a challenging macroeconomic environment.</li><li>As a consequence, the company has revised its full-year revenue projection to between $595 million and $605 million, indicating a 3% decrease from the previous year.</li></ul>

10x Genomics, a leading biotechnology company, presented its financial results for the third quarter ended September 30, 2024, during which the company experienced a 1% year-over-year decline in revenue.This outcome was primarily attributed to disruptions stemming from a sales restructuring initiative and cautious customer spending amid a challenging macroeconomic environment.As a consequence, the company has revised its full-year revenue projection to between $595 million and $605 million, indicating a 3% decrease from the previous year.

10x Genomics Inc.: What Are Their Recent Single-Cell & Spatial Technology Advancements? - Major Drivers

<ul><li>10x Genomics, a leader in single-cell and spatial technologies, presented a mixed financial and operational report for Q2 2024, characterized by modest revenue growth alongside strategic advancements and evident pressures from the external economic environment.</li><li>On the financial front, 10x Genomics reported a revenue increment of 4% year-over-year, reaching $153 million, driven particularly by robust demand for spatial consumables and a sequential increase in single-cell consumables.</li><li>Notably, the company achieved a free cash flow positive status during the quarter.</li></ul>

10x Genomics, a leader in single-cell and spatial technologies, presented a mixed financial and operational report for Q2 2024, characterized by modest revenue growth alongside strategic advancements and evident pressures from the external economic environment.On the financial front, 10x Genomics reported a revenue increment of 4% year-over-year, reaching $153 million, driven particularly by robust demand for spatial consumables and a sequential increase in single-cell consumables.Notably, the company achieved a free cash flow positive status during the quarter.

10x Genomics Inc.: How Are They Adapting to Market Conditions & Customer Needs? - Major Drivers

United States

10X Genomics, Inc. operates as a life science and diagnostics company. The Company develops software for analyzing biological systems such as genetic and immune cells. 10X Genomics serves customers worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

10X Genomics (TXG US)

10X Genomics Inc-Class A - Hybridan Small Cap Feast: 12/03/2025

Aptamer Group 0.33p £6.57m (APTA.L) The developer of novel Optimer binders to enable innovation in the life sciences industry yesterday reported...

Hybridan

Hybridan Small Cap Feast: 12/02/2025

The medical technology Company is focussed on the durable healing of wounds and the prevention of amputations through its unique intermittent...

Hybridan

What's News in Amsterdam - 21 November (Dsm-Firmenich | KPN | Unilever | ForFarmers | PostNL)

In today's edition: • dsm-firmenich | sold its remainder ~1% stake in Robertet • KPN | Delta announced tariff increases as per 1 January...

The IDEA!

10x Genomics Inc.: What Are Their Recent Single-Cell & Spatial Technology Advancements? - Major Drivers

10x Genomics, a leading biotechnology company, presented its financial results for the third quarter ended September 30, 2024, during which the...

Baptista Research

10x Genomics Inc.: How Are They Adapting to Market Conditions & Customer Needs? - Major Drivers

10x Genomics, a leader in single-cell and spatial technologies, presented a mixed financial and operational report for Q2 2024, characterized by...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)